TIAA CREF Investment Management LLC lowered its position in shares of Aratana Therapeutics, Inc. (NASDAQ:PETX) by 13.8% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 237,047 shares of the biopharmaceutical company’s stock after selling 38,069 shares during the period. TIAA CREF Investment Management LLC’s holdings in Aratana Therapeutics were worth $1,256,000 as of its most recent filing with the SEC.

A number of other large investors have also recently added to or reduced their stakes in the stock. Cadence Capital Management LLC raised its stake in Aratana Therapeutics by 21.7% in the first quarter. Cadence Capital Management LLC now owns 131,926 shares of the biopharmaceutical company’s stock worth $699,000 after buying an additional 23,506 shares during the last quarter. American International Group Inc. increased its position in Aratana Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 20,534 shares of the biopharmaceutical company’s stock worth $109,000 after buying an additional 1,354 shares during the period. Baird Financial Group Inc. increased its position in Aratana Therapeutics by 32.0% in the first quarter. Baird Financial Group Inc. now owns 40,758 shares of the biopharmaceutical company’s stock worth $216,000 after buying an additional 9,880 shares during the period. Ray Gerald L & Associates Ltd. increased its position in Aratana Therapeutics by 38.2% in the first quarter. Ray Gerald L & Associates Ltd. now owns 23,900 shares of the biopharmaceutical company’s stock worth $127,000 after buying an additional 6,600 shares during the period. Finally, Capital Fund Management S.A. bought a new position in Aratana Therapeutics during the first quarter worth approximately $282,000. 63.97% of the stock is owned by institutional investors and hedge funds.

Aratana Therapeutics, Inc. (PETX) traded down 1.08% on Tuesday, reaching $5.52. 26,822 shares of the company’s stock were exchanged. Aratana Therapeutics, Inc. has a 12 month low of $4.97 and a 12 month high of $10.73. The firm has a 50 day moving average of $6.94 and a 200 day moving average of $6.37. The stock’s market capitalization is $237.37 million.

Aratana Therapeutics (NASDAQ:PETX) last announced its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.29) by $0.03. Aratana Therapeutics had a negative net margin of 642.93% and a negative return on equity of 51.21%. The business had revenue of $5.16 million for the quarter, compared to analyst estimates of $4.50 million. During the same quarter in the previous year, the firm posted $0.61 earnings per share. Aratana Therapeutics’s revenue was down 86.4% compared to the same quarter last year. Equities analysts predict that Aratana Therapeutics, Inc. will post ($1.07) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Aratana Therapeutics, Inc. (PETX) Position Reduced by TIAA CREF Investment Management LLC” was first published by Watch List News and is owned by of Watch List News. If you are reading this piece on another site, it was stolen and reposted in violation of international copyright legislation. The legal version of this piece can be viewed at https://www.watchlistnews.com/aratana-therapeutics-inc-petx-position-reduced-by-tiaa-cref-investment-management-llc/1490240.html.

A number of research firms have commented on PETX. BidaskClub downgraded shares of Aratana Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, July 19th. ValuEngine upgraded shares of Aratana Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, July 25th. Zacks Investment Research downgraded shares of Aratana Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, May 10th. Finally, Jefferies Group LLC reiterated a “buy” rating and set a $8.00 price objective on shares of Aratana Therapeutics in a research note on Sunday, May 14th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $9.50.

About Aratana Therapeutics

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

Want to see what other hedge funds are holding PETX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aratana Therapeutics, Inc. (NASDAQ:PETX).

Institutional Ownership by Quarter for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Ratings for Aratana Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.